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The long non-coding RNA CRNDE is an oncogene that promotes tumor growth in glioblastoma multi-
forme (GBM). At least ﬁve CRNDE transcript variants with possibly different functional roles have been
described in recent studies. Here, we report our preliminary ﬁndings on the differential expressions of
CRNDE transcript variants in GBM, and their prognostic signiﬁcance. Our preliminary data suggest that
different transcript variants of CRNDE might have different functions in GBM and should be further
studied as potential biomarkers for clinical prognostication.
© 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Glioblastoma multiforme (GBM) is classiﬁed as the most ma-
lignant type of brain cancer characterized by its highly proliferative
and invasive behavior. Patients with GBM have poor clinical out-
comes with a median survival of 14.6 months and 30% two-year
survival following standard treatment. A host of factors account
for its poor prognosis including heterogeneity of cell types, differ-
ential responses to therapies as well as the development of che-
moresistance [1]. The treatment regimen for GBM is multimodal in
nature that includes surgical resection followed by concurrent
chemo-irradiation and chemotherapy with temozolomide [2,3].
Long non-coding RNAs (lncRNAs) have recently emerged as
important regulators in normal biological processes and disease
pathogenesis. Colorectal neoplasia differentially expressed
(CRNDE), one of the most upregulated lncRNAs in GBM [4], has
been identiﬁed to be an oncogene closely associated with malig-
nant phenotypes in glioma [5e7]. It is noteworthy that CRNDE has
different transcript variants resulting from alternative splicing [8].
These transcript isoforms may differ in expression levels and
functions in glioma [6,9]. Here, we investigate the differentialDepartment of Surgery, Li Ka
ng, Queen Mary Hospital, 102
ing by Elsevier B.V. on behalf of Ke
d/4.0/).expression of CRNDE transcript isoforms and provide preliminary
evidence on how they may be further exploited as prognostic
markers in GBM.
2. Materials and methods
2.1. Clinical specimens
A total of 13 GBM specimens (mean age: 53.92 ± 16.05) and
normal brain tissues were retrieved from our institutional tissue
bank. The diagnosis of GBM was conﬁrmed by a certiﬁed patholo-
gist and classiﬁed according to the World Health Organization
(WHO) brain tumor classiﬁcation system [10]. The study protocol
was approved by the Institutional Review Board of our institution,
with signed informed consent obtained from the patients or their
legal guardians before sample collection.
2.2. Cell lines
Human GBM cell lines U87-MG and U138-MG were obtained
from American Type Culture Collection (ATCC, Manassas, VA, USA).
U87-MG and U138-MG were cultured in Minimum essential me-
dium (MEMa) (GIBCO, Invitrogen, Carlsbad, CA, USA) and Dulbec-
co's modiﬁed eagle's medium with high glucose (DMEM
GlutaMAX) (GIBCO), respectively. Media were supplemented with
10% heat-inactivated fetal bovine serum (FBS), 100 IU/mL penicillin,
and 100 mg/mL streptomycin (all from GIBCO). Primary normalAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND
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Fig. 1. Differential expression of CRNDE transcript variants (TV) and its clinical signiﬁcance in glioblastoma multiforme. A) CRNDE is located at Chr 16q12.2 and presented
with different TV. Corresponding exons are illustrated in boxes with different length. NCBI reference (TV-1: NR_034105.3, TV-2: NR_034106.2, TV-3: NR_110453.1, TV-4:
NR_110454.1, TV-5: NM_001308963.1). B) Differential mRNA expressions of TV1-TV5 were detected by qRT-PCR in GBM cell lines (U87 and U138) vs. normal human astrocytes
(NHA) and in GBM specimens vs. normal brain tissues. Graphs show the mean ± SD of three independent experiments. **p < 0.001 C) Kaplan Meier survival curve on TV1 and TV5
expression of GBM specimens. Patients were stratiﬁed by median expression of TV1 and TV5 into two groups (High or Low).
K.M.Y. Kiang, G.K.K. Leung / Non-coding RNA Research 2 (2017) 119e121120human astrocytes (NHA; Lonza, Basel, Switzerland) were used as
non-transformed controls and cultured in DMEM GlutaMAX
(GIBCO). Cells were cultured at 37 C in 5% CO2 and 90% relative
humidity.
2.3. Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted using Trizol reagent (Invitrogen) and
reverse transcribed into cDNA using the reverse transcription kit
(Takara Bio, Shiga, Japan). cDNAs were then mixed with gene-
speciﬁc primers (TV-1: NR_034105.3, TV-2: NR_034106.2, TV-3:
NR_110453.1, TV-4: NR_110454.1 and TV-5: NM_001308963.1) andSYBR reagent (Takara), and ampliﬁed in an ABI Prism 7900HT Fast
Real-Time PCR System. GAPDH was used as an internal control for
PCR quality. mRNA expression levels were analyzed using the 2-DD
Ct calculation method.
2.4. Survival and statistical analysis
For survival analysis, patients were ﬁrst stratiﬁed into low and
high expression groups by using the median expression value of
TV-1 or TV-5 as the cut-off. Kaplan Meier estimation was used to
examine overall survival, and a log-rank test was used to assess the
difference between the two groups. Data analysis was performed
K.M.Y. Kiang, G.K.K. Leung / Non-coding RNA Research 2 (2017) 119e121 121using GraphPad Prism 7.0 (La Jolla, CA, USA). Continuous data were
presented as mean ± SD. The p values were calculated by One-way
ANOVA analysis for comparison of more than 2 groups. P values of
equal or less than 0.05 were considered statistically signiﬁcant.
3. Results and discussion
3.1. Differential expression and clinical signiﬁcance of CRNDE
transcript variants
According to National Center for Biotechnology Information
(NCBI), ﬁve transcript variants (TV1-5) of CRNDE have been re-
ported. These variants are generated through alternative splicing,
and consist of different numbers of exons as illustrated in Fig. 1A. In
a preliminary survey of GBM cell lines and specimens, the expres-
sions of both TV-1 and TV-5 were highly upregulated as compared
to normal astrocytes; TV-2, TV-3 and TV-4 were expressed only in
trace amounts both in normal and malignant brain tissues (Fig. 1B).
To further evaluate the clinical signiﬁcance of these transcripts in
GBM, we performed Kaplan Meier survival analysis based on TV-1
and TV-5 expression among the GBM patient specimens. Interest-
ingly, while the expression levels of TV-1 and TV-5 alone did not
correlate with survival, a trend can be observed between clinical
survival and TV-1 to TV-5 ratio (TV-1:TV-5) on Kaplan Meier
analysis (Fig. 1C). Though the p value in log rank test did not reach
statistical signiﬁcance (p ¼ 0.072), the ﬁndings suggest a potential
clinical utility of CRNDE transcripts expression level in predicting
patient survival.
This ﬁnding also suggests different functional roles among the
CRNDE transcripts. In our preliminary results, a low TV-1:TV-5
ratio was associated with a more favorable disease outcome,
implying that the oncogenic activities of TV-1 and TV-5 may in fact
oppose one another. Indeed, tumor-speciﬁc splice variants have
been discovered in some other cancers [11], and individual variants
may serve as highly speciﬁc “molecular signatures” [12]. The
characterization of these tumor-speciﬁc variants may also allow for
high speciﬁcity targeting therapies on cancerous tissues with only
minimal impact on normal tissues. In that regard, antisense ther-
apies that aimed to modify splicing patterns have been shown to
yield promising results [11,12].
Different functional roles of the two variants of CRNDE have
been described. TV-1, also known as CRNDE-h, is the reference
variant with full-length sequence. Strikingly, it was found that this
variant could be detected in plasma with elevated expressions in
colorectal cancer patients, suggesting that TV-1 isoform may be a
promising biomarker [8,13]. An open reading frame (ORF) hasrecently been identiﬁed on TV-5 which is able to encode for a nu-
clear peptide (CRNDEP). The latter may have functional roles in the
formation of stress granule and the regulation of cell proliferation
[9].4. Conclusion
Our study provides preliminary ﬁndings that direct future in-
vestigations into speciﬁc transcript variants of CRNDE. Researches
that focus on the identiﬁcation of tumor-speciﬁc variants are likely
to become increasingly important for the development of bio-
markers and effective therapeutic strategies.Conﬂicts of interest
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